drugset / Trial / NCT00981357

A Study To Investigate Whether PF-04457845 Is Effective In Treating Pain, Is Safe And Tolerable In Patients With Osteoarthritis Of The Knee

NCT00981357

Phase 2 Completed 76 enrolled Pfizer
RandomizedCrossoverQuadruple-blindTreatment

Summary

Inactivation of the FAAH (Fatty Acid Amide Hydrolase) enzyme has been shown to relieve pain and inflammation in animal studies. PF-04457845 has been shown to inactivate the FAAH enzyme in animals and healthy human volunteers. The purpose of this study is to evaluate whether PF-04457845 can inactivate the FAAH enzyme in patients experiencing pain due to OA and whether this results in these patients experiencing less pain.

Timeline

Start
2009-11
Primary completion
2010-05
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Naproxen Small molecule 500 mg
Subject REDAFAMDASTAT Small molecule 4 mg Oral

Indications